Prostaglandins and hypothalamic neurotransmitter receptors involved in hyperthermia: a critical evaluation.
The role of a prostaglandin of the E series (PGE) in the hypothalamic mechanisms underlying a fever continues to be controversial. This paper reviews the historical literature and current findings on the central action of the PGEs on body temperature (Tb). New experiments were undertaken to examine the local effect of muscarinic, nicotinic, serotonergic, alpha-adrenergic, or beta-adrenergic receptor antagonists at hypothalamic sites where PGE1 caused a rise in Tb of the primate. Guide tubes for microinjection were implanted stereotaxically above sites in and around the anterior hypothalamic, preoptic area (AH/POA) of male Macaque monkeys. Following postoperative recovery, 30-100 ng of PGE1 was micro-injected unilaterally in a volume of 1.0-1.5 microliter at sites in the AH/POA to evoke a rise in Tb, and once identified, pretreated with a receptor antagonist. PGE1 hyperthermia was significantly reduced by microinjections of the muscarinic and nicotinic antagonists, atropine, or mecamylamine, at PGE1 reactive sites in the AH/POA. The serotonergic antagonist, methysergide, injected at PGE1 sensitive sites in the ventromedial hypothalamus also attenuated the rise in Tb. However, the 5-HT reuptake blocker, fluoxetine, and the beta-adrenergic receptor antagonist, propranolol, injected in the AH/POA failed to alter the PGE1 hyperthermia. In contrast, the alpha-adrenergic antagonist, phentolamine, potentiated the increase in Tb at all PGE1 reactive sites in the hypothalamus. An updated model is presented to explain how the concurrent actions of aminergic neurotransmitters acting on their respective receptors in the hypothalamus can interact with a PGE to elicit hyperthermia. Finally, an evaluation of the current literature including recent findings on macrophage inflammatory protein (MIP-1) supports the conclusion that a PGE in the brain is neither an obligatory nor essential factor for the expression of a pyrogen fever.
Simpson
C W
CW
Division of Molecular Biology and Biochemistry, University of Missouri, Kansas City 64108.
Ruwe
W D
WD
Myers
R D
RD
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001833:Body Temperature Regulation / Q000187:drug effects*; D018680:Cholinergic Antagonists; D007031:Hypothalamus / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology*; D007032:Hypothalamus, Anterior / Q000033:anatomy & histology / Q000502:physiology; D007276:Injections, Intraventricular; D008253:Macaca mulatta; D008254:Macaca nemestrina; D008297:Male; D008845:Microinjections; D011301:Preoptic Area / Q000033:anatomy & histology / Q000502:physiology; D011458:Prostaglandins E / Q000008:administration & dosage / Q000494:pharmacology*; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D012702:Serotonin Antagonists; D014697:Ventromedial Hypothalamic Nucleus / Q000033:anatomy & histology / Q000502:physiology
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D018680:Cholinergic Antagonists; D011458:Prostaglandins E; D017981:Receptors, Neurotransmitter; D012702:Serotonin Antagonists